Get the latest news, insights, and market updates on TARS (Tarsus Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board
Tarsus Pharmaceuticals (TARS) shares are back in focus after the company added former Allergan CEO David E. I. Pyott to its Board of Directors, with Pyott also taking key committee roles. See our latest analysis for Tarsus Pharmaceuticals. The board appointment comes after a weaker period for the stock, with a 30 day share price return of an 11.1% decline and a year to date share price return of a 21.7% decline, even as the 3 year total shareholder return is around 4x. If this kind of... Feb 19, 2026 - $TARS
Does Adding Ophthalmology Veteran David Pyott to the Board Change The Bull Case For Tarsus (TARS)?
Tarsus Pharmaceuticals has appointed David E. I. Pyott, former Chairman and CEO of Allergan and current director at several global healthcare companies, to its Board of Directors, where he will serve as a Class III independent director and chair the Commercial Committee. Pyott’s long track record in scaling ophthalmology and specialty pharma franchises, including leading Allergan from about US$1.00 billion to over US$7.00 billion in revenue, directly aligns with Tarsus’s ambition to grow... Feb 19, 2026 - $TARS
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong Feb 18, 2026 - $TARS
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 Feb 17, 2026 - $TARS
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals (TARS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Jan 26, 2026 - $TARS
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally?
If you are wondering whether Tarsus Pharmaceuticals is still worth buying after its big run, you are not alone. This article is going to walk through exactly what the market may be pricing in versus what the fundamentals suggest. The stock has climbed to around $81.83, gaining 2.3% over the last week, about 20.0% over the past month, and 48.4% year to date, with 58.0% over 1 year and 428.6% over 3 years, hinting at a major reset in how investors view its prospects. Recent moves have been... Dec 5, 2025 - $TARS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple